AstraZeneca
AZN
1,288 hedge funds and large institutions have $37.9B invested in AstraZeneca in 2025 Q3 according to their latest regulatory filings, with 160 funds opening new positions, 547 increasing their positions, 358 reducing their positions, and 76 closing their positions.
111% more first-time investments, than exits
New positions opened: 160 | Existing positions closed: 76
91% more funds holding in top 10
Funds holding in top 10: 11 → 21 (+10)
84% more call options, than puts
Call options by funds: $559M | Put options by funds: $303M
53% more repeat investments, than reductions
Existing positions increased: 547 | Existing positions reduced: 358
9% more capital invested
Capital invested by funds: $34.7B → $37.9B (+$3.21B)
5% more funds holding
Funds holding: 1,222 → 1,288 (+66)
0.04% less ownership
Funds ownership: 8% → 7.96% (-0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$219M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$204M |
| 3 |
Holocene Advisors
New York
|
+$137M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$133M |
| 5 |
Goldman Sachs
New York
|
+$126M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$642M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$481M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$213M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$154M |
| 5 |
D.E. Shaw & Co
New York
|
-$127M |
AZN Hedge Fund Activity: Q3 2025 in Review
1,288 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2025, worth a combined $37.9B — up 9.2% from $34.7B a quarter earlier.
Buyers outnumbered sellers: 160 funds opened new AZN positions and 76 closed out — a net gain of 84 holders — while 547 added to existing stakes and 358 trimmed.
The largest buyer was Citigroup, adding an estimated $219M. The largest seller was Jennison Associates, cutting an estimated $642M.
- 1,288 institutional investors held AstraZeneca (AZN) as of Q3 2025, up from 1,222 in Q2 2025.
- Funds reported $37.9B of AstraZeneca stock for Q3 2025, up 9.2% quarter-over-quarter.
- 160 funds opened new AstraZeneca positions in Q3 2025 and 76 closed out, a net change of +84 holders.
- The largest AstraZeneca buyer in Q3 2025 was Citigroup, an estimated $219M added.
- The largest AstraZeneca seller in Q3 2025 was Jennison Associates, an estimated $642M sold.
Based on aggregated 13F filings for Q3 2025.